Global Gabapentin Market Size, Share, Trends, Growth, and Industry Analysis, By Type (Generic and Branded), By Dosage (Tablet, Capsule and Oral Solution), By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), Regional Analysis, Competitor Analysis and Forecast 2024-2032.

Global Gabapentin market size was USD 5.03 billion in 2023 and the market is projected to touch USD 9.36 billion by 2032, at a CAGR of 7.14% during the forecast period. Gabapentin works by calming down overactive nerve signals in the brain, helping to alleviate symptoms such as pain or seizures. The market for gabapentin has seen significant growth in recent years due to its effectiveness in treating various medical conditions, including epilepsy, neuropathic pain, and restless legs syndrome.

The global gabapentin market has grown steadily, driven by increased knowledge of its therapeutic benefits and the rising prevalence of illnesses such as neuropathic pain and epilepsy. The market is distinguished by the existence of several prominent pharmaceutical companies producing gabapentin-based drugs, as well as an increasing number of generic drug makers. Furthermore, the industry has seen significant advances in drug administration systems, such as extended-release formulations, which provide greater convenience and patient compliance. Despite regulatory challenges and concerns regarding the misuse of gabapentin, particularly in combination with other substances, the market is expected to continue its growth trajectory, fuelled by ongoing research and development efforts aimed at expanding its therapeutic indications and improving drug efficacy.

Global Gabapentin report scope and segmentation.

Report Attribute

Details

Base Year

2023

Forecast Years

2024 – 2032

Estimated Market Value (2023)

USD 5.03 Billion

Projected Market Value (2032)

USD 9.36 Billion

Segments Covered

By Type, By Dosage, By Application, By Distribution Channel, & By Region.

Forecast Units

Value (USD Million or Billion)

Quantitative Units

Revenue in USD million/billion and CAGR from 2024 to 2032.

Regions Covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Countries Covered

U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Australia, Brazil, Argentina, GCC Countries, and South Africa, among others.

Download Free Sample Report

Global Gabapentin dynamics

The global gabapentin market is impacted by a variety of factors, including the rising prevalence of illnesses such as epilepsy, neuropathic pain, and anxiety disorders, which drive demand for gabapentin-containing drugs. Furthermore, the aging population and increased knowledge of gabapentin's therapeutic benefits drive market growth. However, the market confronts hurdles like as regulatory scrutiny over gabapentin's off-label use for diseases that have not been permitted by regulatory authorities, as well as worries about its propensity for misuse and addiction, particularly when combined with other medications. Despite these obstacles, the market is driven by continuous research and development initiatives targeted at increasing gabapentin's therapeutic indications, improving drug formulations for greater efficacy and patient compliance, and resolving safety issues. Moreover, the market is characterized by intense competition among pharmaceutical companies, both established players and generic manufacturers, leading to price fluctuations and strategic collaborations to gain market share.

Global Gabapentin drivers

Increasing Prevalence of Neurological Disorders

The rising incidence of neurological disorders such as epilepsy, neuropathic pain, and restless legs syndrome is a significant driver for the gabapentin market. These conditions affect millions of people globally, driving the demand for effective treatments like gabapentin. As awareness about these disorders grows, along with improved diagnosis and healthcare infrastructure, the market for gabapentin is expected to expand further. Additionally, as the aging population increases, the prevalence of neurological disorders is likely to rise, providing a sustained market demand for gabapentin-based medications.

Growing Awareness and Acceptance of Gabapentin

Over the years, healthcare professionals and patients have come to understand and accept gabapentin's therapeutic benefits. Gabapentin's effectiveness in treating a variety of neurological diseases, combined with its comparatively low adverse effect profile when compared to previous treatments, has contributed to its increasing popularity. Furthermore, the extension of gabapentin's approved indications, combined with off-label use in illnesses such as chronic pain and anxiety disorders, expands its commercial potential. As education and awareness initiatives continue to promote gabapentin's benefits and safety profile, the market is positioned to experience sustained growth.

  • Restraints:

Regulatory Scrutiny and Off-label Use Concerns

The off-label use of gabapentin for conditions not approved by regulatory authorities has attracted scrutiny, leading to regulatory concerns and restrictions. While gabapentin is approved for specific indications such as epilepsy and neuropathic pain, its off-label use for conditions like anxiety and mood disorders raises safety and efficacy questions. Regulatory agencies are increasingly monitoring and restricting off-label prescribing, which could limit the market's growth potential for gabapentin.

Misuse and Dependency Risks

There is rising concerned about gabapentin's abuse and dependency potential, especially when combined with other drugs. Reports of gabapentin usage and addiction have sparked concern among healthcare professionals and regulatory organizations. The risk of dependency, combined with the possibility for recreational use and diversion, presents barriers to market growth. Efforts to reduce misuse through regulatory measures and education campaigns may influence prescribing patterns and market dynamics for gabapentin.

  • Opportunities:

Expansion of Therapeutic Indications

Expanding gabapentin's therapeutic potential beyond its existing approved uses represents a huge possibility for market growth. Research into novel gabapentin applications in illnesses such as fibromyalgia, migraine, and psychiatric problems could lead to new opportunities. Clinical research examining the efficacy and safety of gabapentin in various areas may result in additional approvals, thus expanding the market's addressable patient base and revenue potential.

  • Segment Overview

Gabapentin market segmentation by type includes two main categories: generic and branded formulations. Generic gabapentin refers to medications manufactured and sold under their chemical name without a brand name. These products are typically more affordable due to competition from multiple manufacturers after the expiration of patent protection for branded formulations. On the other hand, branded gabapentin medications are developed and marketed by pharmaceutical companies under a specific brand name, often accompanied by extensive marketing efforts to distinguish them from generic counterparts. While branded products may offer certain advantages such as proprietary drug delivery technologies or extended-release formulations, generic gabapentin dominates the market in terms of volume due to its lower cost and widespread availability.

Gabapentin drugs come in a variety of dose forms, including pills, capsules, and oral solutions. The most generally prescribed dosage forms are tablets and capsules, which provide patients with convenient administration and exact dosing. These solid oral dosage forms are recommended because they are stable, easy to manufacture, and suitable for a wide range of patient populations. Oral solutions are an option for patients who have difficulties swallowing solid dose forms or need individualized dosing. The choice of dose form depends on criteria such as patient preference, medical condition, and healthcare provider's suggestion. Tablets and capsules are the favoured options for most patients due to their familiarity and convenience.

Global Gabapentin Overview by Region

North America dominates the market, owing to high healthcare spending, extensive R&D activity, and broad gabapentin use for a variety of purposes. The European market is distinguished by a developed pharmaceutical sector, strict regulatory frameworks, and increased demand for gabapentin due to the increasing prevalence of neurological diseases. The Asia-Pacific area offers lucrative growth potential, supported by increased healthcare access, rising disposable income, and increased awareness of neurological illnesses, which drives demand for gabapentin. In Latin America, the Middle East, and Africa, market growth is affected by factors such as expanding healthcare infrastructure, increased investment in healthcare, and rising illness burden associated with neurological disorders. However, challenges such as limited access to healthcare services, affordability issues, and regulatory barriers may hinder market growth in these regions.

Global Gabapentin market competitive landscape

Key players such as Pfizer, Teva Pharmaceutical Industries, and Mylan N.V. dominate the market with their branded and generic gabapentin formulations, leveraging their strong distribution networks, extensive product portfolios, and brand recognition. These companies make large investments in R&D to develop novel formulations, increase therapeutic indications, and improve drug delivery systems, with the goal of differentiating their products and maintaining competitive advantages. Furthermore, strategic collaborations, partnerships, and mergers and acquisitions are frequent methods used by players to increase market presence, expand geographic reach, and exploit complementary talents. The competitive landscape is further strengthened by the arrival of new competitors and the emergence of regional manufacturers offering lower-cost alternatives, spurring price competition and market consolidation efforts among industry incumbents.

Global Gabapentin Recent Developments

  • March 2024, Strides Pharma Science Limited (Strides) has been granted approval by the United States Food & Drug Administration (USFDA) for Gabapentin Tablets USP in 600 mg and 800 mg strengths. This marks a significant expansion of Strides' product range, aiming to address the requirements of patients with neurological conditions. The approval, disclosed through an exchange announcement, was awarded to Strides Pharma Global Pte Limited, Singapore.
  • Sept 2023, Lotus Pharmaceutical, a prominent global pharmaceutical firm, collaborates with B2B pharma leader, Adalvo, to proudly unveil Gabapentin ER 300 / 600 mg in South Korea. This innovative 505b(2) product, developed from the renowned Neurontin Hard Capsule 300mg and Neurontin Film Coated Tablet 600mg, aims to provide enduring relief for individuals suffering from Postherpetic Neuralgia (PHN). PHN, a debilitating ailment, can severely impact one's quality of life. Gabapentin ER, featuring a convenient once-daily dosing schedule, promises to significantly enhance patient convenience and overall treatment experience.

Scope of global Gabapentin report

Global Gabapentin report segmentation

ATTRIBUTE

DETAILS

By Type
  • Generic
  • Branded

By Dosage
  • Tablet
  • Capsule
  • Oral Solution

By Application
  • Epilepsy
  • Neuropathic Pain
  • Restless Legs Syndrome
  • Others

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Customization Scope
  • Available upon request

Pricing
  • Available upon request

Table of Contents

  1. 1. Market Scope and Research Methodology
    1. Market Segmentation & Scope
    2. Market Definition
    3. Research Methodology
      1. Our Internal Database
      2. Paid Sources Database
      3. Secondary Sources & Third-Party Perspectives
      4. Primary Research, Experts Interviews and Market Surveys
    4. Research Objective
    5. Data Validation & Publishing
  2. 2. Executive Summary
    1. Market Outlook
    2. Segmental Analysis
  3. 3. Gabapentin Market Dynamics
    1. Market Introduction
    2. Market Drivers
      1. Increasing prevalence of neurological disorders such as epilepsy, neuropathic pain, and restless leg syndrome
      2. Growing geriatric population worldwide, which is more susceptible to neuropathic pain and related disorders
    3. Market Restraints
      1. Concerns regarding the misuse and abuse of gabapentin, particularly in cases of substance abuse and addiction
      2. Side effects associated with gabapentin use, including dizziness, drowsiness, and weight gain
    4. Industry Challenges
    5. Industry Opportunities
    6. Regulatory Frameworks
    7. Patent Trends
    8. Covid-19 Impact Analysis
    9. Market Strategic Analysis
      1. Industry Analysis – Porter’s
        1. Supplier Power
        2. Buyer Power
        3. Substitution Threat
        4. Threat from New Entrant
        5. Competitive Rivalry
      2. PESTEL Analysis
      3. Consumer behaviour analysis
        1. Consumer response to the product
        2. Factors affecting buying decision
        3. Other recommendations
  4. 4. Gabapentin Market: Type Estimates & Trend Analysis
    1. Type Movement Analysis & Market Share, 2023 & 2032
    2. Generic
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    3. Branded
      1. Market estimates and forecast, 2024-2032, (USD Billion)
  5. 5. Gabapentin Market: Dosage Estimates & Trend Analysis
    1. Dosage Movement Analysis & Market Share, 2023 & 2032
    2. Tablet
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    3. Capsule
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    4. Oral Solution
      1. Market estimates and forecast, 2024-2032, (USD Billion)
  6. 6. Gabapentin Market: Application Estimates & Trend Analysis
    1. Application Movement Analysis & Market Share, 2023 & 2032
    2. Epilepsy
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    3. Neuropathic Pain
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    4. Restless Legs Syndrome
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    5. Others
      1. Market estimates and forecast, 2024-2032, (USD Billion)
  7. 7. Gabapentin Market: Distribution Channel Estimates & Trend Analysis
    1. Distribution Channel Analysis & Market Share, 2023 & 2032
    2. Hospital Pharmacy
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    3. Retail Pharmacy
      1. Market estimates and forecast, 2024-2032, (USD Billion)
    4. Online Pharmacy
      1. Market estimates and forecast, 2024-2032, (USD Billion)
  8. 8. Gabapentin Market: Regional Estimates & Trend Analysis
    1. Regional Movement Analysis & Market Share, 2023 & 2032
    2. North America
      1. Market estimates and forecast, 2024-2032, (USD Billion)
      2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
      3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
      4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
      5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      6. U.S.
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      7. Canada
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
    3. Europe
      1. Market estimates and forecast, 2024-2032, (USD Billion)
      2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
      3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
      4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
      5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      6. Germany
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      7. UK
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      8. France
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      9. Spain
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      10. Rest of Europe
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
    4. Asia Pacific
      1. Market estimates and forecast, 2024-2032, (USD Billion)
      2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
      3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
      4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
      5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      6. China
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      7. India
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      8. Japan
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      9. South Korea
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      10. Australia
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      11. Southeast Asia
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      12. Rest of Asia Pacific
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
    5. Middle East & Africa
      1. Market estimates and forecast, 2024-2032, (USD Billion)
      2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
      3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
      4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
      5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      6. GCC
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      7. Turkey
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      8. Africa
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      9. Rest of MEA
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
    6. Latin America
      1. Market estimates and forecast, 2024-2032, (USD Billion)
      2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
      3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
      4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
      5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      6. Brazil
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      7. Mexico
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      8. Argentina
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
      9. Rest of Latin America
        1. Market estimates and forecast, 2024-2032, (USD Billion)
        2. Market estimates and forecast, by Type, 2024-2032, (USD Billion)
        3. Market estimates and forecast, by Dosage, 2024-2032, (USD Billion)
        4. Market estimates and forecast, by Application, 2024-2032, (USD Billion)
        5. Market estimates and forecast, by Distribution Channel, 2024-2032, (USD Billion)
  9. 9. Competitive Analysis
    1. Key global players, recent developments & their impact on the industry
    2. Key Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
    3. Vendor Landscape
      1. Key company market share analysis, 2021
  10. 10. Company Profiles
    1. Apotex Inc.
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    2. Sun Pharmaceutical Industries Ltd.
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    3. Novartis AG
      1.  Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    4. Glenmark Pharmaceuticals Ltd
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    5. Mylan N.V
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    6. Hikma Pharmaceuticals PLC
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    7. Pfizer Inc.
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    8. Aurobindo Pharma Ltd.
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    9. Lupin Limited.
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    10. Dr. Reddy's Laboratories Ltd.
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    11. Cadila Healthcare Ltd
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    12. Teva Pharmaceutical Industries Ltd.
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    13. Amneal Pharmaceuticals, Inc.
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis
    14. Torrent Pharmaceuticals Ltd.
      1. Company Overview
      2. Financial Analysis
      3. Product Benchmarking
      4. Key development
      5. Business Strategy
      6. SWOT Analysis


In case you don’t find what, you are looking for, please get in touch with our custom research team at sales@organicmarketresearch.com or Download Free Sample Report

  • What is the study period of global Gabapentin report?
    Global Gabapentin forecast period is 2024 - 2032
  • What is the expected global Gabapentin growth rate during the forecast period?
    According to global Gabapentin research, the market is expected to grow at a CAGR of ~ 7.14% over the next eight years.
  • What is the expected market size for Global Gabapentin?
    The expected market size for Global Gabapentin is USD 9.36 billion in 2032.
  • What are the possible segments in global Gabapentin?
    The possible segments in global Gabapentin are based on By Type, By Dosage, By Application, By Distribution Channel, & by region.
  • Who are the key players in Global Gabapentin?
    The major players in the market are Apotex Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Glenmark Pharmaceuticals Ltd., Mylan N.V., Hikma Pharmaceuticals PLC, Pfizer Inc., Aurobindo Pharma Ltd., Lupin Limited, Dr. Reddy's Laboratories Ltd., Cadila Healthcare Ltd. (Zydus Cadila), Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., and Torrent Pharmaceuticals Ltd..
  • Buy Now

Speak To Consultant

or Face to Face Meeting

Why Choose Us

  • 24x7 Post-Sales Support
  • 4000+ Reports Repository
  • 10% Free Customization
  • Large Network Of Industry Experts
  • Deep Sector Specific Intelligence
  • Unique Mix Of Global, Regional And Country Specific Reports

Related Reports

Recent News

Why Buy From Us?

Succeed

Our reports with in-depth insights will equip you to succeed in your business plans.

Instant Access

Get instant access to the information you need to make the right decision.

Opportunities

Explore where opportunities lie for you and mitigate the risks.

Trusted

We are one of the most trusted brands setting benchmarks of excellence.